Its compounding-pathway status shifted in April 2026 when the FDA removed it from Category 2 of the 503A bulk substances list, though this is a compounding determination, not an approval
Patients with controlled uric acid level and doing well on allopurinol would seem to have no reason to switch to this new agent, in view of allopurinol's lower cost and 40-year history of an overall very good safety record (see "Allopurinol" discussion above)
For patients without absorption disorders, high-dose oral B12 supplements (1,000-2,000 mcg daily) have been shown to be comparably effective to injections in correcting mild to moderate deficiency
For example, there was no information on how much of the active ingredient the product contained, any warnings about dosage, or a list of any ingredients
Timeline: What to Expect During Recovery Reported timelines vary, but anecdotal users claim: 12 weeks : Reduced pain and inflammation
Contact us for an appointment today: